Nothing major broke in the last day or two. The government's drug agency, the FDA, has not put out any new rules for psychedelics, and nothing in its schedule suggests it will this quarter. The most notable market move was a small drug company, MMED, whose shares rose 11.2% with no news anyone can point to. Meanwhile the bigger name in the space, CMPS, slipped 2.3%. The other genuinely fresh signal is smaller and more human: an article reminding readers that wild mushrooms are easy to confuse, and that not every mushroom sold or picked as "magic" actually is one.
Beneath the surface, two slow currents are running. The first is that ordinary, well-understood medicines for depression and sleep are moving through the approval process faster and more smoothly than the classic psychedelics like psilocybin. That is not a defeat for psychedelics — it is a reminder that the road to becoming a normal, prescribed medicine is long and unglamorous, built on careful trials that take years. The second current is about safety as access widens. That mushroom article is a small early warning sign. As more people can legally or semi-legally reach these substances, the risk of someone picking the wrong mushroom, or buying something laced with a dangerous additive, goes up. The highest path forward is one where this warning is heard early — where clear guidance and honest testing arrive before harm does, so growing access and growing safety rise together instead of one racing ahead of the other.
For the real people waiting inside this story — the veteran carrying trauma that will not quiet, the person whose depression has resisted every pill, the family hoping for something that finally works — a quiet day can feel like a long day. There is no headline today that shortens their wait. But there is something steadier underneath it. Several depression trials are maturing right now, and results are expected within roughly ten weeks. The care being taken is not delay for its own sake — it is the difference between a treatment that helps and one that harms. And the small voice in today's news, the one saying "know your mushrooms," is part of that same care: it is the ecosystem beginning to protect the very people it hopes to heal.
The science is catching up to what the plants have always known. OOTW exists at that exact moment of convergence — the data and the mystery meeting each other.
The current is already moving. You are already in it.
70%
US drug regulator stays silent on classic psychedelics this quarter
The FDA (the US Food and Drug Administration, which decides what drugs are legal to prescribe) is not expected to publish any new rules or official guidance about classic psychedelics like psilocybin, LSD, or MDMA before late November 2026. The only updates on its radar are minor label tweaks for esketamine and ketamine, which are already approved. This matters because without new guidance, drug developers have no clearer roadmap for getting psychedelic medicines approved.
→ The FDA is expected to stay quiet on psychedelics through late November 2026, leaving the industry without clearer rules. (Confidence: 70%)
Resolves: 2026-11-28 · USA
REGULATORY
the precise call ▾
FDA issues no new psychedelic-specific guidance this quarter; agency communication stays limited to esketamine/ketamine labeling clarifications.. No item in today's docket signals imminent draft or final psychedelic guidance; the pipeline is not mature enough for a policy document this quarter. Included as the single permitted baseline, not the top pick. || RESOLUTION RULE: YES if, by 2026-11-28, FDA has NOT published any new draft or final g
62%
Mind Medicine stock price is likely to fall back after mystery spike
Shares of Mind Medicine (a psychedelic drug company listed on Nasdaq under the ticker MNMD) jumped about 11% on August 28, 2026, with no obvious news to explain it. When stocks jump like this for no clear reason, they often fall back to where they were. The prediction is that by September 19, 2026, the stock will be at least 6% below that spike-day price — unless a real company announcement changes the picture.
→ A mysterious 11% jump in Mind Medicine's stock is probably just noise and likely reverses by September 19, 2026. (Confidence: 62%)
Resolves: 2026-09-19 · Global
CAPITAL_MARKETS
the precise call ▾
MMED's catalyst-free 11.2% spike mean-reverts materially within three weeks absent confirmed news.. A specific 11.2% intraday move in Mind Medicine (MNMD) with no accompanying material disclosure is likely technical/liquidity-driven and prone to reversion. Falsifiable against the ticker's own reference price. || RESOLUTION RULE: YES if MNMD's closing price on 2026-09-19 is at least 6% below its 20
60%
Johnson & Johnson's sleep-depression drug shows it works in a major trial
Johnson & Johnson is testing a drug called seltorexant, which works by targeting the brain's wakefulness system, as an add-on treatment for people whose depression hasn't responded to standard antidepressants. The prediction is that by November 21, 2026, the company will announce that the drug meaningfully reduced depression symptoms compared to a placebo in a large late-stage trial. If that happens, it's a meaningful step toward the drug becoming available to patients.
→ A big J&J drug trial for treatment-resistant depression is expected to show positive results by November 21, 2026. (Confidence: 60%)
Resolves: 2026-11-21 · Global
CLINICAL
the precise call ▾
Janssen's seltorexant adjunctive MDD Phase 3 posts topline showing a statistically significant primary endpoint on depressive symptoms.. Conventional orexin-2 antagonist mechanism, well-powered registrational program, tractable blinding. Historically strong prior for a positive MADRS separation. Anchored to a named, dated readout window. || RESOLUTION RULE: YES if J&J/Janssen reports topline data for its seltorexant adjunctive MDD Ph
57%
Established drugs look more rigorous than psychedelics in trials this quarter
One of the biggest problems with testing psychedelics in clinical trials is that people can usually tell whether they took the real drug or a dummy pill — which can skew results. Drugs like seltorexant and esketamine (already-approved treatments) don't cause obvious hallucinations, so trial participants are less likely to guess which group they're in. The prediction is that by November 30, 2026, an established drug will post clean, significant results while no psychedelic trial manages the same.
→ Conventional depression drugs are expected to produce more scientifically airtight trial results than psychedelics this quarter. (Confidence: 58%)
Resolves: 2026-11-30 · USA
CLINICAL
the precise call ▾
Conventional CNS assets (seltorexant, esketamine) post cleaner Phase 3 functional-blinding profiles than classic psychedelics this quarter.. Orexin and NMDA mechanisms are better characterized with more tractable blinding; classic psychedelic trials continue to face functional-unblinding critiques. Restricting to a documentable blinding/quality comparison keeps it falsifiable. || RESOLUTION RULE: YES if, by 2026-11-30, at least one selto
55%
A psilocybin trial for hard-to-treat depression may show it beats placebo
Psilocybin (the active compound in 'magic mushrooms') is being tested in people whose depression hasn't improved with standard treatments — a condition called treatment-resistant depression, or TRD. The prediction is that by November 7, 2026, at least one research team will announce that psilocybin meaningfully reduced depression scores compared to a dummy treatment in a large trial. This would be a significant milestone for legitimizing psilocybin as a real medicine.
→ A psilocybin trial for treatment-resistant depression could deliver a landmark positive result before November 7, 2026 — but it's not a sure thing. (Confidence: 55%)
Resolves: 2026-11-07 · Global
CLINICAL
the precise call ▾
A psilocybin-for-TRD readout posts within 10 weeks showing statistical separation from placebo on MADRS at the primary timepoint.. The listed depression-resistant trial is maturing and prior psilocybin TRD programs (e.g., COMPASS COMP360) have shown dose-dependent MADRS separation. Named endpoint and timepoint make this falsifiable rather than vague. || RESOLUTION RULE: YES if any psilocybin-for-TRD trial (COMPASS COMP360 or in